Elimination of hcv-infection: a history with continuation
https://doi.org/10.22625/2072-6732-2018-10-4-6-13
Abstract
Chronic hepatitis C remains one of the most important socially significant infections for world health. The use of modern highly effective drugs with direct antiviral action allows to achieve a sustained virological response in patients. At the same time, in a significant number of cases after elimination of HCV infection, the progression of fibrosis continues with the development of its terminal stages and an unfavorable outcome for patients. The article focuses on comorbid pathology, which is a leading factor in this process in patients with chronic hepatitis C who have achieved a sustained virological response and presenting a serious challenge to modern hepatology.
About the Authors
K. V. Zhdanov
Military Medical Academy named after S.M. Kirov, Saint-Petersburg
Russian Federation
Russian Federation
K. V. Kozlov
Military Medical Academy named after S.M. Kirov, Saint-Petersburg
Russian Federation
Russian Federation
V. S. Sukachev
Military Medical Academy named after S.M. Kirov, Saint-Petersburg
Russian Federation
Russian Federation
S. M. Zaharenko
Military Medical Academy named after S.M. Kirov, Saint-Petersburg
Russian Federation
Russian Federation
S. S. Karyakin
Military Medical Academy named after S.M. Kirov, Saint-Petersburg
Russian Federation
Russian Federation
A. V. Saulevich
Military Medical Academy named after S.M. Kirov, Saint-Petersburg
Russian Federation
Russian Federation
D. Yu. Lobzin
Military Medical Academy named after S.M. Kirov, Saint-Petersburg
Russian Federation
Russian Federation
M. V. Yaryemenko
Military Medical Academy named after S.M. Kirov, Saint-Petersburg
Russian Federation
Russian Federation
K. S. Ivanov
Military Medical Academy named after S.M. Kirov, Saint-Petersburg
Russian Federation
Russian Federation
Yu. I. Lyashenko
Military Medical Academy named after S.M. Kirov, Saint-Petersburg
Russian Federation
Russian Federation
V. E. Karev
Pediatric Research and Clinical Center for Infectious Diseases, Saint-Petersburg
Russian Federation
Russian Federation
Yu. F. Zaharkiv
Military Medical Academy named after S.M. Kirov, Saint-Petersburg
Russian Federation
Russian Federation
Yu. I. Bulan’kov
Military Medical Academy named after S.M. Kirov, Saint-Petersburg
Russian Federation
Russian Federation
References
1. Stanaway J.D. et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. The Lancet. 2016 Sep; 388 (10049): 1081–1088.
2. Zhdanov K.V., Kozlov K.V., Sukachev V.S., Zhabrov S.S. Infektcionnie bolezni. 2018. №16(2). С: 98–103 (in Russian).
3. Dyson J., et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol. 2014 Jan; 60 (1):110-117
4. Satapathy S.K., Sanyal A.J. Epidemiology and natural history of nonalcoholic fatty liver disease. Semin. Liver Dis. 2015; 35: 221–35.
5. Ivashkin V.T., Drapkina O.M., Mayev I.V. et. al. Ros. Jurnal gastroenterologii, gepatologii, coloproctologii. 2015; 24 (6): 31 – 41 (in Russian).
6. Adinolfi L.E., Rinaldi L., Guerrera B. et al. NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations. International Journal of Molecular Sciences. 2016; 6 (17): 803.
7. Zhdanov K.V., Karjakin S.S., Kozlov K.V. et. Vestnik Rossiyskoy Voenno-medicinskoy akademii. 2018; 61(1): 216–21 (in Russian).
8. Dulai P.S., Singh S., Patel J., Soni M., Prokop L.J., Younossi Z., et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology 2017; 65: 1557-1565.
9. Caligiuri A., Gentilini A., Marra F. Molecular pathogenesis of NASH. International Journal of Molecular Sciences. 2016; 17 (9):1575.
10. Crum-Cianflone N., Dilay A., Collins G., et al. Nonalcoholic Fatty Liver Disease (NAFLD) among HIV-Infected Persons. J. Acquir. Immune Defic. Syndr. 2009; 50(5): 464–73.
11. Puoti M, Moioli MC, Travi G, Rosootti R. The burden of liver disease in HIV-infected patients. Semin Liver Dis. 2012; 32:103-13.
12. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and HCV: 2007 updated recommendations from the HCV-HIV Inter- national Panel. AIDS 2007; 21:1073-89.
13. Van Der Helm J, et al. Effect of HCV Infection on CauseSpecific Mortality After HIV Seroconversion, Before and After 1997. Gastroenterology, 2013; 144:751–760.
14. Asselah T., Rubbia-Brandt L., Marcellin P., Negro F. Steatosis in chronic hepatitis C: why does it really matter? Gut. 2006; 55: 123-130.
15. Price J.C. Liver Disease in the HIV-Infected Individual. Clin. Gastroenterol. Hepatol. 2010; 8(12): 1002 – 1012.
16. Zhdanov K.V., Kozlov K.V., Sukachev V.S. VICH-infektciya I immunosupressii. 2017; 1(9): 36-42 (in Russian).
17. Guaraldi G. et. al. Nonalcoholic Fatty Liver Disease in HIVInfected Patients Referred to a Metabolic Clinic: Prevalence, Characteristics, and Predictors. HIV/AIDS. 2008; 47: 250 – 257.
18. Pinzani M. Fatty Liver Disease: co-factor of HCV and evolving disease entity [Internet]. Available from: http://congress-ph.ru/common/htdocs/upload/fm/gepatology/2016/prez/2-1-1.pdf.
19. Sukachev V.S. Otcenka morfofunktcional’nogo sostoyaniya tonkoy kishki u bol’nih hronicheskim gepatitom C [Assessment of a morfofunktsionalny condition of a small bowel at patients with chronic hepatitis C]: Avtoref. dis. …kand. med. nauk. SPb.; 2012.
20. Zhdanov K.V., Gusev D.A., Zaharenko S.M. et. al. Zhurnal eksperimental’noy i klinicheskoy gastroenterologii. 2011; 6: 38 – 44 (in Russian).
21. Zhdanov K.V., Gusev D.A., Zaharenko S.M. et. al. Zhurnal infektologii. 2011; 3(4): 98 – 101 (in Russian).
22. Trivedi P. J., Adams D.H. Gut-liver immunity. J Hepatol 2016; 64: 1187-89.
23. Schneider K.M., Albers St., Trautwein Ch. Role of bile acids in the gut-liver axis. J Hepatol. 2018; 68:1083–1085.
24. Brandl K., Hartmann P., Jih L.J. Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. J. Hepatol. 2018 Aug; 69(2): 396–405
25. R. Schwabe, EASL 2018 (oral presentation). https://ilccongress.eu/wp-content/uploads/2018/04/EASL_ILC-scientific-programme-2018.pdf
26. Zubkin M.L., Semenenko T.A., Sel’kova E.P. Infekcionnie bolezni. 2017;15(4): 68 – 76 (in Russian).
27. Negro F., Forton D., Craxi A., Sulkowski M.S., Feld J.J., Manns M.P. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology. 2015 Nov; 149(6): 1345-60.
28. Dammaco F., Racanelli V., Russi S., Sansonno D. The expanding spectrum of HCV-related cryoglobulinemic vasculitis: a narrative review // Clin Exp Med. 2016 Aug; 16(3): 233-42.
29. Dore G.J., Altice F., Litwin A.H., et al. Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. Ann Intern Med. 2016; 165: 625-634.
30. Grebely J., Mauss S., Brown A., et al. Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials. Clin Infect Dis. 2016; 63:1405-1411.
31. Grebely J., Dore G.J., Zeuzem S. et al. Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials. Clin Infect Dis. 2016;63:1479-1481.
32. Grebely J, et al. EASL 2017. Abstract FRI-235.
33. https://www.hcvguidelines.org
34. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol (2016).
35. Konerman M.A., Jones J.C., Harrison S.A. Pharmacotherapy for NASH: Current and emerging. J Hepatol. 2018; 68: 362-75.
Review
For citations:
Zhdanov K.V., Kozlov K.V., Sukachev V.S., Zaharenko S.M., Karyakin S.S., Saulevich A.V., Lobzin D.Yu., Yaryemenko M.V., Ivanov K.S., Lyashenko Yu.I., Karev V.E., Zaharkiv Yu.F., Bulan’kov Yu.I. Elimination of hcv-infection: a history with continuation. Journal Infectology. 2018;10(4):6-13. (In Russ.) https://doi.org/10.22625/2072-6732-2018-10-4-6-13
Views:
1433
.png)
.png)
Email this article 